Comparative Analysis of Cancer Treatment Duration, Cost, and Survival by Cancer Type

Overview

Cancer treatment varies substantially across cancer types due to differences in tumor biology, staging at diagnosis, and therapeutic modalities. This document presents a comparative analysis of five major cancers: breast cancer, colorectal cancer, lung cancer, prostate cancer, and hematologic malignancies. Each section examines typical treatment duration, cost, and survival outcomes based on 2025–2026 clinical data.

Breast Cancer

Breast cancer treatment often involves multimodal therapy including surgery, radiation, chemotherapy, endocrine therapy, and targeted therapy. Chemotherapy typically lasts three to five months, radiation therapy four to six weeks, and endocrine therapy five to ten years. Targeted therapies such as trastuzumab and pertuzumab may extend for one year or longer.

Total treatment costs range from sixty thousand to one hundred fifty thousand dollars, depending on stage and targeted therapy use. Early‑stage breast cancer has a five‑year survival rate exceeding ninety percent, while metastatic breast cancer has median survival of approximately three years with modern HER2‑targeted and CDK4/6‑targeted therapies.

Colorectal Cancer

Colorectal cancer treatment typically includes surgery followed by adjuvant chemotherapy for stage III disease. Chemotherapy regimens such as FOLFOX or CAPOX last three to six months. Radiation therapy is used primarily for rectal cancer and lasts five to six weeks. Metastatic colorectal cancer treatment may continue indefinitely with chemotherapy and targeted agents.

Total treatment costs range from seventy thousand to two hundred thousand dollars. Stage III colorectal cancer has a five‑year survival rate of approximately sixty‑five percent. Metastatic colorectal cancer has response rates of thirty to forty percent and median survival of twenty to twenty‑four months.

Lung Cancer

Lung cancer treatment varies significantly between non‑small‑cell lung cancer (NSCLC) and small‑cell lung cancer (SCLC). NSCLC treatment may include surgery, chemotherapy, radiation, immunotherapy, and targeted therapy. Chemotherapy typically lasts three to four months, radiation therapy six to seven weeks, and immunotherapy up to two years. Targeted therapies for EGFR, ALK, ROS1, and KRAS mutations may continue indefinitely.

Total treatment costs often exceed one hundred thousand dollars, particularly when immunotherapy or targeted therapy is used. Early‑stage NSCLC has a five‑year survival rate of sixty to seventy percent. Metastatic NSCLC treated with immunotherapy has median survival of approximately two years. SCLC has median survival of twelve to eighteen months for limited‑stage disease and five to seven months for extensive‑stage disease.

Prostate Cancer

Prostate cancer treatment frequently includes surgery, radiation therapy, androgen‑deprivation therapy, and in advanced cases, chemotherapy or targeted therapy. Radiation therapy typically lasts seven to nine weeks. Androgen‑deprivation therapy may continue for two to three years. Chemotherapy regimens such as docetaxel last three to four months.

Total treatment costs range from forty thousand to one hundred thousand dollars. Localized prostate cancer has a five‑year survival rate exceeding ninety‑eight percent. Metastatic castration‑resistant prostate cancer has median survival of approximately two years with modern therapies.

Hematologic Malignancies

Hematologic cancers include leukemias, lymphomas, and myeloma. Treatment duration varies widely. Acute leukemias require multi‑phase chemotherapy lasting six to twelve months. Chronic leukemias may require lifelong targeted therapy. Lymphoma treatment typically lasts three to six months, while multiple myeloma treatment may continue indefinitely with maintenance therapy.

Total treatment costs range from eighty thousand to two hundred fifty thousand dollars. Childhood acute lymphoblastic leukemia has survival rates of eighty to ninety percent. Chronic myeloid leukemia treated with tyrosine kinase inhibitors has ten‑year survival exceeding ninety percent. Multiple myeloma has median survival of five to seven years with modern therapy.

Comparative Summary Table

Cancer Type	Treatment Duration	Cost Range	Survival Outcomes
Breast Cancer	Three months to one year; endocrine therapy up to ten years	Sixty thousand to one hundred fifty thousand dollars	Over ninety percent for early‑stage; three years median for metastatic
Colorectal Cancer	Three to six months; longer for metastatic therapy	Seventy thousand to two hundred thousand dollars	Sixty‑five percent for stage III; twenty to twenty‑four months median for metastatic
Lung Cancer	Three to seven months; immunotherapy up to two years	Over one hundred thousand dollars	Sixty to seventy percent early‑stage; two years median for metastatic NSCLC; five to eighteen months for SCLC
Prostate Cancer	Seven to nine weeks radiation; ADT two to three years	Forty thousand to one hundred thousand dollars	Over ninety‑eight percent localized; two years median for metastatic castration‑resistant
Hematologic Malignancies	Six months to lifelong depending on subtype	Eighty thousand to two hundred fifty thousand dollars	High cure rates for childhood ALL; over ninety percent ten‑year survival for CML; five to seven years median for myeloma